Published in Gene Therapy Weekly, May 15th, 2003
Advexin is Introgen's p53 gene based cancer therapeutic being evaluated in two phase III studies, five phase II clinical studies, and numerous phase I studies totaling studies in 10 cancers. INGN 241, an mda-7 gene based cancer therapeutic, is being evaluated in phase I and phase II trials for various solid tumors. Both products are covered by multiple issued and pending patents...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly